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Activated Protein C Prevents Neuronal Apoptosis
via Protease Activated Receptors 1 and 3
injury (Shibata et al., 2001; Cheng et al., 2003). It also
prevents p53-dependent apoptosis in hypoxic endothe-
lium in vitro and in vivo through endothelial protein
Huang Guo,1 Dong Liu,2 Harris Gelbard,3
Tong Cheng,2 Rae Insalaco,1 Jose´ A. Ferna´ndez,4
John H. Griffin,4 and Berislav V. Zlokovic1,2,*
C receptor (EPCR)-dependent activation of protease ac-1Socratech Laboratories
tivated receptor 1 (PAR1) (Cheng et al., 2003). Its directRochester, New York 14620
effects on endothelial cells require EPCR and PAR1 (Rie-2 Frank P. Smith Neurosurgical Research Laboratory
wald et al., 2002; Cheng et al., 2003; Domotor et al.,Department of Neurosurgery
2003; Mosnier and Griffin, 2003).Center of Aging and Developmental Biology
It is not clear, however, whether APC can protect directlyDivision of Neurovascular Biology
perturbed neurons by activating PARs, or whether APC’sUniversity of Rochester Medical Center
neuroprotection is secondary to its antithrombotic andRochester, New York 14642
anti-inflammatory activities or its anti-apoptotic activity3 Department of Neurology
in brain endothelium (Cheng et al., 2003). PARs, G pro-University of Rochester Medical Center
tein-coupled receptors, are activated by proteolytic cleav-Rochester, New York 14642
age by various proteases that results in an intramolecu-4 Department of Molecular and Experimental Medicine
lar tethered ligand that triggers intracellular signalingThe Scripps Research Institute
(Coughlin, 2000; Coughlin and Camerer, 2003; Bahou,La Jolla, California 92037
2003). PAR1 was first discovered as a human platelet
thrombin receptor (Vu et al., 1991), and today four ho-
mologous PARs are known in man and mice (Coughlin
and Camerer, 2003; Bahou, 2003). The various PARs areSummary
differentially expressed in various cells and tissues, and
all four PARs are expressed in the central nervous sys-Activated protein C (APC), a serine protease with anti-
tem (Striggow et al., 2001). The effects of activation ofcoagulant and anti-inflammatory activities, exerts direct
each PAR by specific protease in any given organ orcytoprotective effects on endothelium via endothelial
cell type generally remain to be elucidated.protein C receptor-dependent activation of protease
We hypothesized that APC’s interaction with PARs inactivated receptor 1 (PAR1). Here, we report that APC
neurons is neuroprotective. To test this hypothesis, weprotects mouse cortical neurons from two divergent
studied two divergent inducers of neuronal apoptosis:inducers of apoptosis, N-methyl-D-aspartate (NMDA)
N-methyl-D-aspartate (NMDA), using in vitro (Bonfocoand staurosporine. APC blocked several steps in NMDA-
et al., 1995) and in vivo (Ayata et al., 1997) models of NMDA-induced apoptosis downstream to nitric oxide, i.e.,
induced neuronal injury, and staurosporine (Budd et al.,caspase-3 activation, nuclear translocation of apopto-
2000). Overstimulation of NMDA receptors is implicatedsis-inducing factor (AIF), and induction of p53, and
in stroke, brain trauma, and neurodegenerative disor-prevented staurosporine-induced apoptosis by blocking
ders such as Alzheimer’s disease and Huntington’s dis-caspase-8 activation upstream of caspase-3 activa-
ease (Le and Lipton, 2001; Kemp and McKernan, 2002).tion and AIF nuclear translocation. Intracerebral APC
The mechanisms involved in NMDA-induced neuronalinfusion dose dependently reduced NMDA excitotoxi-
apoptosis include generation of nitric oxide (Dawson etcity in mice. By using different anti-PARs antibodies
al., 1991; Ayata et al., 1997), activation of caspase-3and mice with single PAR1, PAR3, or PAR4 deletion,
and -7 (Du et al., 1997; Tenneti and Lipton, 2000; Okamotowe demonstrated that direct neuronal protective ef-
et al., 2002), nuclear translocation of apoptosis-inducing
fects of APC in vitro and in vivo require PAR1 and
factor (AIF) and activation of PARP-1 (poly(ADP)-ribose
PAR3. Thus, PAR1 and PAR3 mediate anti-apoptotic polymerase-1) (Yu et al., 2002), and increases in p53
signaling by APC in neurons, which may suggest novel and Bax (Sakhi et al., 1997; Uberti et al., 1998; Djebaili
treatments for neurodegenerative disorders. et al., 2000; Jordan et al., 2003). Staurosporine, but not
NMDA, targets caspase-8 upstream of caspase-3 acti-
Introduction vation (Budd et al., 2000). It may induce apoptosis inde-
pendent of p53 (Jordan et al., 2003; Villunger et al.,
Activated protein C (APC) is a serine protease with 2003), although involvement of p53 at later stages of
systemic anticoagulant and anti-inflammatory activities staurosporine-mediated apoptosis has been suggested
(Griffin et al., 2002). The best-known activity of APC is (Tieu et al., 1999; Alves da Costa et al., 2003). Here, we
its anticoagulant activity. However, the direct effects of show that APC protects against NMDA-induced apopto-
APC on cells are subject to increasing attention. Recent sis in mouse cortical neurons by blocking caspase-3
studies demonstrate that APC reduces organ damage activation, nuclear translocation of AIF, and induction
in animal models of sepsis (reviewed in Griffin et al., of p53, and prevents staurosporine-induced apoptosis
2002) and in humans with severe sepsis (Bernard et al., by blocking caspase-8 activation upstream of caspase-3
2001), represses apoptosis in the developing placenta activation and AIF nuclear translocation. Intracerebral
(Isermann et al., 2003), and protects brain from ischemic infusion of APC dose dependently reduced NMDA exci-
totoxicity in mice. By using different anti-PARs antibod-
ies and mice with single PAR1 (Coughlin, 2000), PAR3,*Correspondence: berislav_zlokovic@urmc.rochester.edu
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Figure 1. APC Blocks NMDA-Induced Apoptosis in Mouse Cortical Neurons
(A) Immunostaining for TUNEL and Hoechst 24 hr after NMDA in the absence or presence of human APC (hAPC, 100 nM).
(B) Effect of hAPC (100 nM) on NMDA-induced apoptosis as a function of time; apoptotic cells were quantified with TUNEL and Hoechst.
Control spontaneous rate of apoptosis is also illustrated (solid points, control).
(C) Dose-dependent neuroprotective effects of hAPC and recombinant mouse APC (mAPC) at 24 hr of NMDA; control rate of apoptosis (solid
point) and rate of apoptosis in the presence of NMDA only (open point) are also illustrated.
(D) TUNEL-positive cells in experiments as in (A) in the presence of Ac-DEVD-CHO (50 M) or hAPC (100 nM). *p  0.05, **p  0.01 compared
with values in the absence of APC.
or PAR4 deletion (Nakanishi-Matsui et al., 2000), we tive cells that were also TUNEL positive (Figure 2A) were
demonstrated that direct neuronal protective effects of significantly reduced by60% by APC (Figure 2B). APC
APC in vitro and in vivo require both PAR1 and PAR3. significantly reduced capsase-3 activity in a time-depen-
dent manner (Figure 2C) but did not affect caspase-8
activity (data not shown), consistent with the previousResults
report (Budd et al., 2000). Next, we confirmed nuclear
translocation of AIF in response to NMDA (Yu et al.,Figure 1A illustrates that the number of TUNEL-positive
2002) at 18 and 24 hr and demonstrated that both APCcells with apoptotic nuclear changes in NMDA-per-
and/or Ac-DEVD-CHO efficiently block AIF translocationturbed mouse cortical neurons was significantly reduced
(Figures 2D and 2E).by human plasma-derived APC (100 nM) 24 hr after NMDA
We confirmed that NMDA induces generation ofchallenge. APC reduced the number of TUNEL-positive
cGMP, which is an indirect sensitive measure of NOcells in a time-dependent manner including earlier and
production (Figure 3A; Dawson et al., 1991). Generationlater time points at 12 and 36 hr of exposure to NMDA
of cGMP was inhibited by nitric oxide synthase (NOS)(Figure 1B). Figure 1C shows dose-dependent neuronal
inhibitors N-arginine and L-NAME as reported (Dawsonprotection by human and mouse recombinant APC. The
et al., 1991), but not by APC (Figure 3A). L-arginine re-IC50 values for reducing neuronal apoptosis for human
versed the effect of NOS inhibitors (not shown). In re-and mouse APC were 49 and 5 nM, respectively, confirm-
sponse to NMDA treatment, there was an early increaseing significantly higher efficacy of the species homolo-
in p53 protein and mRNA (Figures 3B and 3C), possiblygous mouse APC, consistent with a recent report in a
related to increased NO production (Morrison et al.,mouse stroke model (Cheng et al., 2003). Ac-DEVD-CHO,
2003; Bru¨ne and Schneiderhan, 2003). The present dataa specific inhibitor of caspase-3 activation, blocked
demonstrate that NOS inhibitors prevent induction ofNMDA-induced apoptosis (Figure 1D), consistent with
p53 in NMDA-treated neurons, while L-arginine reversesseveral reports (Du et al., 1997; Tenneti and Lipton, 2000;
the effect on NOS inhibitors (Figure 3D), consistent withBudd et al., 2000; Okamoto et al., 2002). Inhibition by
previous report (Dawson et al., 1991). APC significantlyAc-DEVD-CHO was comparable to that obtained by APC
reduced by half the increased levels of p53 protein inraising a possibility that APC may block pro-apoptotic
nuclear extracts of NMDA-treated neurons (Figures 3Bcaspase-3 activation.
In response to NMDA, the number of caspase-3-posi- and 3F) and the levels of p53 mRNA transcripts (Figure
APC-PAR1/PAR3 Interaction in Neurons Is Protective
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Figure 2. Effects of APC on Caspase-3 and AIF in NMDA-Treated Neurons
(A) Caspase-3, TUNEL, and Hoechst triple staining 24 hr after NMDA in the absence or presence of human APC (hAPC, 100 nM).
(B) Caspase-3-positive cells 24 hr after NMDA with and without hAPC (100 nM).
(C) Caspase-3 activity in cultured cortical neurons; time course after exposure to NMDA  hAPC (100 nM).
(D) Western blot analysis of AIF in nuclear extracts from NMDA-treated cells and the effects of murine APC (mAPC, 10 nM) and Ac-
DEVD-CHO (50 M) on AIF nuclear translocation.
(E) Intensity of AIF nuclear signal measured by scanning densitometry and effect of mAPC and Ac-DEVD-CHO in experiments as in (D). Data
are mean  SEM (3–5 independent experiments in triplicate). *p  0.05 compared with values in the absence of APC.
3C). Phosphorylation of p53 on Ser20 or Ser15, which et al., 2001) or indirectly due to generation of plasmin
(Matys and Strickland, 2003). In contrast to reportedwould stabilize the protein by preventing its proteosomal
degradation by precluding its binding to the oncoprotein effects for tPA (Nicole et al., 2001) and/or plasminogen
(Matys and Strickland, 2003), APC did not cleave themurine double minute-2 (Mdm2), was undetectable ei-
ther in nuclear extracts or whole cell homogenates (not NMDA receptors subunits (Figure 3H) and also did not
alter NMDA-stimulated fura-2 fluorescence signal (notshown). Changes in Mdm2 protein in response to NMDA
were undetectable, and direct effects of APC on Mdm2 shown). Thus, APC does not modify the structure nor
does it block the NMDA receptors. Since blocking NMDAprotein were not observed (not shown).
Figures 3E and 3F show that NMDA increases Bax as receptors or modifying their structure could be deleteri-
ous, the current strategies are centered on blockingsuggested (Djebaili et al., 2000) and decreases Bcl-2.
Consistent with p53 blockage, APC blunted the increases NMDA-induced apoptosis downstream to the NMDA re-
ceptors (Aarts et al., 2002).in Bax and the decreases of Bcl-2 (Figures 3E and 3F),
thus normalizing the Bax/Bcl-2 ratio. Since NMDA may To define the specificity of APC’s neuroprotection, we
demonstrated that neither mutant Ser360Ala-APC norincrease the levels of nuclear factor kB (NF-B) (McInnis
et al., 2002) that can be either anti-apoptotic or pro- protein C zymogen could protect neurons from NMDA-
induced apoptosis, and that heat denaturation or anti-apoptotic (Ryan et al., 2000), we tested whether the
observed changes in p53 expression are downstream APC IgG abrogated APC’s activity (Figure 4A). This con-
firms that the active site serine of APC is necessary forto NF-B. Under present experimental conditions, NMDA
did not induce NF-B translocation into the nucleus in neuronal protection and suggests that PARs may be
involved. To test the role of PARs, first we studied thecortical cells (Figure 3G), whereas the positive control
E. coli lipopolysacharide did cause NF-B translocation neuronal protective effects of mouse recombinant APC
in the presence of various anti-PAR antibodies (Figurein umbilical vein endothelium (Figure 3G).
We also studied whether APC affects NMDA receptor 4B). The presence of PAR1, PAR2, PAR3, and PAR4
in the present model has been confirmed by positivestructure and function. Tissue plasminogen activator
(tPA) action on NMDA receptors may involve proteolysis immunostaining on mouse cortical neurons (not shown),
as reported (Striggow et al., 2001). Antibody blockageof the NR1 subunit either due to tPA direct action (Nicole
Neuron
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Figure 3. APC Blocks p53 Induction in NMDA-Treated Neurons
(A) cGMP formation 10 min after NMDA application in the presence of mouse APC (mAPC, 10 nM) and N-arginine (100M) and L-NAME (500M).
(B and C) Western blots (B) for p53 in nuclear protein extracts and RT-PCR (C) for p53 mRNA from NMDA-treated cells in the absence or
presence of human APC (hAPC, 100 nM).
(D) Western blots for p53 in the presence of Me-arginine (100 M), L-NAME (500 M), and N-arginine (100 M) and reversal by L-arginine
(100 M).
(E) Western blots for Bax and Bcl-2 on whole-cell extracts from experiments as in (B).
(F) Intensity of p53, Bax, and Bcl-2 signals normalized to -actin in response to NMDA and the effect of hAPC (100 nM).
(G) NF-B DNA binding activities following exposure of neurons to NMDA; HUVEC exposed to LPS (E. coli ) was a positive control.
(H) Western blots of NMDA receptor subunits NR1 and NR2A in membrane fractions 24 hr after treatment with hAPC (100 nM) for 24 hr. Data
are mean  SEM (3–5 independent experiments for each studied time point).
of the PAR1 cleavage site, but not of the PAR2 cleavage To determine whether APC’s in vivo neuroprotection
requires PAR1 and PAR3, we studied the effects of intra-site, caused significant (70%) loss of APC-mediated
neuronal protection (Figure 4B). In negative controls, cerebral APC on NMDA-induced lesions in mice after
stereotactic injections of NMDA into the caudate nu-antibodies against the N-terminal, cleavage-independent
regions of PAR1 and PAR2, or against the C terminus of cleus (Ayata et al., 1997). Local administration of mouse
APC (0.2 g) significantly reduced by 70% the volumePAR4, were without effect (Figure 4B). An antibody against
the extracellular N-terminal 103 amino acids of PAR3 of NMDA-induced lesions determined at 48 hr after
NMDA injection (Figures 5A and 5B); this neuronal pro-significantly blocked APC-mediated neuronal protection
(65%), in contrast to a control anti-PAR3 antibody tective effect of APC was dose dependent (Figure 5B),
similar to the in vitro results (Figure 1C). There wasagainst the C terminus of PAR3 (Figure 4B). Combination
of antibodies that each partially blocked activation of 70% loss of APC neuroprotective effect in vivo in mice
treated with APC plus anti-PAR1 antibody (Figure 5C)PAR1 and PAR3 completely abrogated APC’s neuronal
protective effects (Figure 4B). We also demonstrated and65% loss of APC-mediated neuroprotection in the
presence of anti-PAR3 antibody. As in vitro (Figure 4B),that PAR1 agonist peptide, TFLLRNPNDK, but not the
PAR2 agonist peptide (SLIGRL), protected neurons combination of antibodies that each partially blocked
activation of PAR1 and PAR3 abolished APC’s neuro-against NMDA-induced apoptosis (Figure 4B). The es-
sential role of PAR1 was confirmed by a complete loss of protective effects in vivo (Figure 5C).
Studies in PAR1 null, PAR3 null, and PAR4 null miceAPC-mediated neuronal protection in neurons cultured
from PAR1 null mice (Figure 4C). of NMDA-induced lesions in the absence and presence
APC-PAR1/PAR3 Interaction in Neurons Is Protective
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Figure 4. PAR1 and PAR3 Mediate APC’s Neuroprotection in NMDA-Treated Neurons
(A) Cortical neurons treated with NMDA in the presence of vehicle, human APC (hAPC), protein C zymogen, anti-APC IgG (C3), Ser360Ala-
APC, and boiled hAPC at 100 nM; apoptotic cells were quantified as in Figure 1.
(B) Cortical neurons treated with NMDA and incubated with mouse APC (mAPC, 10 nM) and various cleavage site blocking PAR1, PAR2, and
PAR3 antibodies (20 g/ml); N-terminal blocking PAR1 and PAR2 antibodies and C-terminal blocking PAR3 and PAR4 antibodies (20 g/ml)
were negative controls. TFLLRNPNDK (10 M) and SLIGRL (100 M), PAR1 and PAR2 agonist peptides, respectively.
(C) Lack of mAPC (10 nM) effect on NMDA-induced apoptosis in neurons cultured from PAR1 null mice. Values are mean  SEM (n  3–5
independent experiments in triplicate). *p  0.01, NMDA versus NMDA  TFLLRNPNDK; NS, nonsignificant.
of APC indicated that APC-mediated neuroprotection Next, we studied whether PARs are involved in APC’s
was lost by approximately 84% and 72% in PAR1 null neuroprotection in staurosporine model. As in NMDA
and PAR3 null mice relative to controls, respectively, model, both mouse and human APC protected mouse
while deletion of PAR4 gene did not result in loss of neurons against staurosporine insult, but higher dose
APC-mediated neuroprotection (Figure 5D). of human APC was needed for the same level of protec-
To test whether APC can also protect neurons against tion. We demonstrated that neither mutant Ser360Ala-
an alternative apoptotic stimulus distinct from NMDA, APC nor protein C zymogen could protect neurons from
we studied its neuroprotective effects in a model of staurosporine-mediated apoptosis, and that heat dena-
staurosporine-induced apoptosis associated with acti- turation or anti-APC IgG abrogated APC’s activity (Fig-
vation of caspase-8, which is not involved in NMDA- ure 7A). Antibody blockage of the PAR1 cleavage site,
mediated apoptosis (Budd et al., 2000). Our data indi- but not PAR2 cleavage site, caused 75% loss of APC-
cate that APC can prevent staurosporine-mediated mediated cytoprotection, while an antibody against the
apoptosis (Figure 6A) by blocking activation of cas- extracellular N-terminal 103 amino acids of PAR3
pase-8 (Figure 6B) upstream of caspase-3 (Figure 6C). blocked by 69% APC-mediated neuroprotection (Figure
We confirmed that selective inhibitors of caspase-8 7B). Combination of antibodies that each partially
(z-IEDT-fmk) and caspase-3 (Ac-DEVD-CHO) block blocked activation of PAR1 and PAR3 almost completely
staurosporine-induced apoptosis (Figure 6A) and that inhibited APC’s neuroprotective effects (Figure 7B), con-
inhibition of caspase-8 activation results in blockade of firming that PAR1 and PAR3 are required for APC’s neu-
caspase-3 activation (Figure 6B), as reported (Budd et roprotection against staurosporine similar as they are
al., 2000). APC prevented AIF translocation from mito- required for APC’s neuroprotection against NMDA toxic-
chondria to nucleus downstream to caspase-8 and -3 ity in vitro (Figures 4B and 4C) and in vivo (Figures 5C
(Figures 6D and 6E), as demonstrated by inhibition of and 5D).
the AIF mitochondrial to nuclear translocation by both
z-IETD-fmk and Ac-DEVD-CHO (Figures 6D and 6E). In
Discussionaddition, we confirmed that activation of caspase-3 by
staurosporine does not require p53, as demonstrated
Recent studies in endothelial cells show that APC acti-by unchanged levels of p53 protein (Figure 6F) prior and
vates PAR1 in an EPCR-dependent manner, alters intra-at the time of increased caspase-3 activation (Figure
cellular signaling, causes alterations in gene expression6C). This result is consistent with a recent report demon-
profiles, and exerts direct anti-apoptotic effects (Joycestrating staurosporine-induced activation of caspase-3
in p53-deficient cells (Paitel et al., 2004). et al., 2001; Riewald et al., 2002; Cheng et al., 2003;
Neuron
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Figure 5. PAR1 and PAR3 Mediate APC’s Neuronal Protection against NMDA In Vivo
(A) Coronal sections of mouse brains infused with NMDA in the absence of mouse APC (mAPC	) or presence of mAPC (mAPC; 0.2 g).
(B) Dose-dependent protective effect of mAPC on NMDA-induced injury in mouse striatum.
(C) Effects of different anti-PAR antibodies on NMDA lesion volumes in the absence or presence of mAPC (0.2 g); antibodies were used at
0.2 g.
(D) NMDA lesion in PAR1 null, PAR3 null, and PAR4 null mice in the absence and presence of mAPC (0.2 g). Values are mean  SEM, n 
3–5 mice; NS, nonsignificant.
Domotor et al., 2003; Mosnier and Griffin, 2003; Ruf, 2003). Lipton, 2000; Budd et al., 2000; Okamoto et al., 2002).
The differences could be related to the different ampli-Here, we present evidence that APC is able to influence
the function of neurons through PAR1 and PAR3 by tude and duration of NMDA-induced signaling, which
likely may influence the prevailing apoptotic cascade.interfering with several pathways of NMDA-induced and
staurosporine-induced apoptotic cascades. Our data Several lines of evidence suggest that p53 is a key
upstream initiator of neuronal cell death in the maturesuggest that APC does not interfere with NMDA-induced
NO generation (Dawson et al., 1991; Ayata et al., 1997), nervous system following diverse number of insults, e.g.,
excitotoxic injury including NMDA (Uberti et al., 1998;but prevents both caspase-3 activation (Du et al., 1997;
Tenneti and Lipton, 2000; Okamoto et al., 2002) and Djebaili et al., 2000; Jordan et al., 2003), ischemia, sei-
zure activity, and X radiation (Morrison et al., 2003).nuclear translocation of AIF, a mitochondrial flavopro-
tein, released in response to NMDA (Yu et al., 2002). In On the other hand, diverse cytotoxic insults such as
cytokine withdrawal, phorbol ester, and staurosporinecase of staurosporine-induced apoptosis, APC prevents
activation of caspase-8 upstream to activation of cas- may induce p53-independent apoptosis in various cell
types (Villunger et al., 2003; Jordan et al., 2003). Ourpase-3 and nuclear translocation of AIF.
As AIF induces apoptotic changes in purified nuclei data in NMDA-treated neurons suggest that APC blocks
transcriptionally dependent p53 induction downstreamin the presence of caspase inhibitors (Susin et al., 1999),
it has been assumed that its function is caspase inde- to NO but upstream of caspase-3 activation. By reducing
Bax/Blc-2 ratio, APC can stabilize the mitochondrial mem-pendent. However, AIF is released from mitochondria after
cytochrome c release subsequent to activation of cas- brane to cytochrome c, thus precluding activation of
caspases (Penninger and Kroemer, 2003). On the otherpases (Arnoult et al., 2002). Consistent with the present
findings in NMDA-mediated and staurosporine-medi- hand, AIF release from mitochondria could be p53 de-
pendent and Bax dependent (Cregan et al., 2002) orated neuronal apoptosis, it has been recently shown
that AIF acts downstream to caspases in both C. elegans PARP-1 dependent (Yu et al., 2002). Thus, by downregu-
lating p53 and Bax in neurons, APC may prevent AIF(Wang, 2001) and human cells (Arnoult et al., 2002; Pen-
ninger and Kroemer, 2003; Gabriel et al., 2003). A recent release from mitochondria. Consistent with this con-
cept, APC-induced increased expression of Bcl-2 mayreport failed to demonstrate NMDA-induced caspase-3
activation (Yu et al., 2002) in contrast to the present and also prevent AIF release (Susin et al., 1999). Our data in
staurosporine model indicate that APC may also preventseveral previous reports (Du et al., 1997; Tenneti and
APC-PAR1/PAR3 Interaction in Neurons Is Protective
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Figure 6. APC Blocks Staurosporine-Induced Apoptosis in Mouse Cortical Neurons
(A) Effect of mAPC (10 nM), z-IEDT-fmk (20 M), and Ac-DEVD-CHO (50 M) on staurosporine (STS, 0.5 M)-induced apoptosis; apoptotic
cells were quantified with TUNEL and Hoechst as in Figure 1.
(B) Caspase-8 activity in cultured cortical neurons; time course after exposure to STS  mAPC (10 nM).
(C) Caspase-3 activity in cultured cortical neurons; time course after exposure to STS in the absence and presence of mAPC (10 nM) and
z-IEDT-fmk (20 M).
(D) Western blot analysis of AIF in nuclear extracts from STS-treated cells and the effects of murine APC (mAPC, 10 nM), z-IEDT-fmk (20 M),
and Ac-DEVD-CHO (50 M) on AIF nuclear translocation.
(E) Intensity of AIF nuclear signal measured by scanning densitometry and effect of mAPC, z-IEDT-fmk, and Ac-DEVD-CHO in experiments
as in (D).
(F) Western blots for p53 in nuclear protein extracts after STS  mAPC (10 nM). Data are mean  SEM (3–5 independent experiments in
triplicate). *p  0.05 compared with values in the absence of APC or z-IEDT-fmk.
AIF release by activating an alternative anti-apoptotic Our studies indicate that whereas PAR3 and PAR4,
but not PAR1, are required for normal action of thrombinpathway through blockade of caspase-8 activation up-
stream of caspase-3 activation, which does not require on mouse platelets (Nakanishi-Matsui et al., 2000), PAR1
and PAR3, but not PAR4, are required for optimal inAPC’s inhibition of p53-mediated pro-apoptotic sig-
naling. vitro and in vivo neuronal protective action of APC. PAR1
Figure 7. PAR1 and PAR3 Mediate APC’s
Neuroprotection against Staurosporine
(A) Cortical neurons treated with stauro-
sporine (STS, 0.5 M) in the presence of vehi-
cle, mouse APC (mAPC, 10 nM), human APC
(hAPC, 100 nM)), human protein C zymogen
(100 nM), human anti-APC IgG (C3), human
Ser360Ala-APC (100 nM), and boiled mAPC
(10 nM); apoptotic cells were quantified with
TUNEL and Hoechst.
(B) Cortical neurons treated with STS and in-
cubated with mouse APC (mAPC, 10 nM) and
cleavage site blocking PAR1, PAR2, and PAR3
antibodies (20 g/ml); C-terminal blocking
PAR4 antibody (20 g/ml) was negative con-
trol. Values are mean  SEM (n  3–5 inde-
pendent experiments in triplicate).
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MA). The medium suppresses glial growth to 2% of the total cellagonist peptide and thrombin at higher concentrations
population. The absence of astrocytes was confirmed by the lackcan kill neurons (Donovan and Cunningham, 1998; Strig-
of glial fibrillary acidic protein (not shown). Cultures were maintainedgow et al., 2000), but at concentrations comparable to
in a humidified 5% CO2 incubator at 37
C for 7 days before treatment.those used in the present study, the PAR1 agonist pro- Medium was replaced every 3 days.
tects cortical rat neurons and astrocytes from hypogly-
cemia and oxygen/glucose deprivation (Donovan and NMDA-Induced Apoptosis in Neuronal Culture
For induction of neuronal apoptosis, cultures were exposed for 10Cunningham, 1998; Striggow et al., 2000). Thus, activa-
min to 300 M NMDA/5 M glycine in Mg2-free Earle’s balancedtion of PAR1 in neurons may be anti-apoptotic, as in
salt solution (EBSS) (Bonfoco et al., 1995). Control cultures werethe case of APC and very low dose thrombin. The pro-
exposed to EBSS alone. After the exposure, cultures were rinsed
apoptotic activity of higher levels of thrombin might in- with EBSS, returned to the original culture medium, and incubated
volve the action of thrombin on substrates other than with different concentrations of either human APC (1–100 nM) or
PAR1 (e.g., PAR4) and/or differences in amplitude and recombinant mouse APC (1–100 nM) for 0, 3, 6, 12, 24, and 36 hr,
protein C zymogen (100 nM), anti-APC IgG (C3, 11 g/ml), Ser360-duration of PAR1 signaling. Although no data show di-
Ala-APC (100 nM), or boiled APC (100 nM) for 24 hr. Ac-DEVD-CHOrect APC cleavage of PAR1 or PAR3 in cells, APC can
(50 M) and z-IETD-fmk (20 M) were applied 3 hr prior to NMDAcleave a synthetic PAR1 N-terminal polypeptide at
treatment. Different anti-PAR antibodies (20 g /ml) were added
Arg41, the thrombin cleavage site, at a rate 5000 times to the incubation medium simultaneously with APC after NMDA
slower than thrombin (Kuliopulos et al., 1999). Further exposure. In typical inhibition experiments, we used either 100 nM
studies are needed to clarify if APC directly activates human plasma-derived APC (hAPC) or 10 nM mouse recombinant
APC (mAPC). TFLLRNPNDK (10 M) and SLIGRL (100 M) werePAR3, if PAR3 is cofactor for PAR1 activation by APC,
added to the incubation medium after NMDA exposure.if PAR3 contributes to PAR heterodimerization, or if
PAR3 in neurons acts by a hitherto unknown mech-
Staurosporine-Induced Apoptosis in Neuronal Cultureanism.
Staurosporine (0.5 M, 0.05% DMSO) was added to the culture
In summary, this study shows that APC interactions medium for 0, 3, 6, 12, 18, 24, and 48 hr. Controls were exposed to
with PAR1 and PAR3 on neurons can protect neurons 0.05% DMSO. Ac-DEVD-CHO (50 M) and z-IETD-fmk (20 M) were
against divergent inducers of apoptosis, which could applied 3 hr prior to staurosporine treatment.
be of importance for developing new therapeutic strate-
Detection of Apoptosisgies to treat neurodegenerative disorders.
Apoptotic cells were visualized by in situ terminal deoxynucleotidyl
transferase-mediated digoxigenin-dUTP nick-end labeling (TUNEL)Experimental Procedures
assay according to manufacturer’s instructions (Intergen Company,
Purchase, NY). Cells were counterstained with the DNA bindingReagents
fluorescent dye, Hoechst 33342 (Molecular Probes, Eugene, OR) atN-methyl-D-aspartate (NMDA) was purchased from Sigma (St.
1 mg/ml for 10 min at room temperature to reveal nuclear morphol-Louis, MO) and staurosporine from Calbiochem (San Diego, CA).
ogy. The number of apoptotic cells was expressed as the percentageHuman APC, recombinant mouse APC, protein C zymogen, mutant
of TUNEL-positive cells of the total number of nuclei determined bySer360Ala-APC, and mouse IgG against human APC (C3 antibody)
Hoechst staining. The cells were counted in 10–20 random fieldswere prepared as reported (Shibata et al., 2001; Cheng et al., 2003;
(30 magnification) by two independent observers blinded to theFernandez et al., 2003). Unless otherwise indicated, for Western blot
experimental conditions. The number of apoptotic cells under basalanalysis or immunostaining we obtained and used antibodies as
conditions (vehicle only) was subtracted from the number of apo-previously described (Cheng et al., 2003). For immunoblotting or
ptotic cells in various experimental groups.immunostaining, we employed the following: polyclonal rabbit anti-
body against human AIF (1:1000, 1 mg/ml; Chemicon, Temecula,
In Situ DNA Fragmentation/Caspase-3 StainingCA), human p53 (1:1000, Cell Signaling, Beverly, MA), and human
Subsequent to visualization of fragmented DNA with TUNEL, cellsNMDA1 (NR1, 1:1000, 0.2 mg/ml; Santa Cruz Biotechnology, Santa
were permeabilized with 0.4% Tween 20 for 30 min and blockedCruz, CA) that all crossreact with the corresponding mouse antigens;
with 10% normal goat serum in PBS for 30 min at room temperature.mouse NR2A (1:500, 1 mg/ml; Upstate Biotechnology, Lake Placid,
A primary anti-caspase-3 antibody was applied overnight at 4
C.NY); and mouse Bax (1:100, Chemicon). All antibodies against PARs
After washing in PBS three times, cells were incubated with Rhoda-were from Santa Cruz Biotechnology, and various antibodies were
mine-conjugated goat anti-rabbit IgG (1:150) for 1 hr at 37
C.used that all crossreact with the corresponding mouse PARs. Poly-
clonal goat antibodies against N terminus of mouse PAR1 (S-19)
Caspase-3 and -8 Activityand mouse PAR2 (S-19) and against the C terminus of mouse PAR3
Cells were washed with PBS and resuspended in cell lysis buffer.(M-20) and mouse PAR4 (M-20) were used as negative controls.
50 l of lysates was incubated with 50 M caspase-3 (DEVD-pNA)Miscellaneous chemical reagents were obtained as described
or caspase-8 (IETD-pNA) substrate at 37
C (ApoAlert caspase assay(Cheng et al., 2003). The peptides, Ac-DEVD-CHO (caspase-3) and
kit, Clontech, Palo Alto, CA). Substrate hydrolysis was determined asz-IETD-fmk (caspase-8) were obtained selected on the basis of sub-
absorbance change at 405 nm in a microplate reader and enzymaticstrate specificity (Budd et al., 2000) and were from Sigma. N-Nitro-
activity was expressed in arbitrary units per mg of protein.L-arginine methyl ester (L-NAME), N-Nitrol-L-arginine (N-Arg), and
L-arginine were purchased from Sigma. N-monomethyl-L-arginine
(Me-Arg) was obtained from Calbiochem. NOS inhibitors were ap- Western Blot Analyses
plied at 100–500 M. Whole cellular extracts and nuclear proteins or cell membrane frac-
tions were prepared and protein concentration determined using
Bradford protein assays (Bio-Rad, Hercules, CA); 10–50 g of pro-Neuronal Cultures
Primary neuronal cultures were established as described (Bonfoco tein was analyzed by 10% SDS-PAGE and transferred to nitrocellu-
lose membranes that were then blocked with 5% nonfat milk in TBSet al., 1995). In brief, cerebral cortex was dissected from fetal C57BL/
6J mice or PAR1 null mice (Coughlin, 2000) at 16 days of gestation, (100 mM, Tris [pH 8.0], 1.5 M NaCl, 0.1% Tween 20) for 1 hr. The
membranes were incubated overnight with primary antibodies intreated with trypsin for 10 min at 37
C, and dissociated by trituration.
Dissociated cell suspensions were plated at 5  105 cells per well TBS and then washed and incubated with a horseradish peroxidase-
conjugated secondary antibody for 1 hr. Immunoreactivity was de-on 12-well tissue culture plates or at 4  106 cells per dish on 60
mm tissue culture dishes coated with poly-D-lysine, in serum-free tected by using the ECL detection system (Amersham, Piscataway,
NJ). The relative abundance of each protein was determined byNeurobasal medium plus B27 supplement (GIBCO-BRL, Rockville,
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scanning densitometry, using -actin as an internal control. Data Received: September 10, 2003
Revised: October 5, 2003from multiple Western blots (n  3–5) were averaged for statisti-
cal analysis. Accepted: January 7, 2004
Published: February 18, 2004
Reverse Transcription-Polymerase Chain Reaction Analysis
ReferencesTotal RNA was isolated from cells and RT-PCR analyses of p53 and
GPDH were performed as described (Cheng et al., 2003).
Aarts, M., Liu, Y., Liu, L., Besshoh, S., Arundine, M., Gurd, J.W.,
Wang, Y.T., Salter, M.W., and Tymianski, M. (2002). Treatment of
ischemic brain damage by perturbing NMDA receptor-PSD-95 pro-cGMP Assay
tein interactions. Science 298, 846–850.Ten minutes after NMDA application with or without NOS inhibitors,
the cells were lysated with 0.1 N HCL. cGMP was assayed with an Alves da Costa, C., Mattson, M.P., Ancolio, K., and Checler, F. (2003).
Amersham 3H-labeling assay kit per manufacturer’s instructions. The C-terminal fragment of presenilin 2 triggers p53-mediated stau-
rosporine-induced apoptosis, a function independent of the preseni-
linase-derived N-terminal counterpart. J. Biol. Chem. 278, 12064–Electrophoretic Mobility Shift Assay
12069.Nuclear proteins were extracted from cortical neuronal cultures at
Arnoult, D., Parone, P., Martinou, J.C., Antonsson, B., Estaquier,0, 0.5, 1, 2, 3, and 6 hr after exposure to NMDA using NE-PER nuclear
J., and Ameisen, J.C. (2002). Mitochondrial release of apoptosis-and cytoplasmic extraction reagents according to manufacturer’s
inducing factor occurs downstream of cytochrome c release in re-instructions (Pierce, Rockford, IL). Human umbilical vein endothelial
sponse to several proapoptotic stimuli. J. Cell Biol. 159, 923–929.cells (HUVEC) were exposed to lipopolysaccharide (LPS) (E. coli,
200 ng/ml) for 4 hr as a positive control. The activation of NF-B Ayata, C., Ayata, G., Hara, H., Mattews, R.T., Beal, M.F., Ferrante,
was determined by its binding to the consensus sequence (5 AGT R.J., Endres, M., Kim, A., Christie, R.H., Waeber, C., et al. (1997).
TGA GGG GAC TTT CCC AGG 3). Briefly, NF-B consensus oligonu- Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric
cleotides (Promega, WI) were labeled using digoxigenin gel shift kit oxide synthase knock-out mice. J. Neurosci. 17, 6908–6917.
(Roche, Indianapolis, IN). Labeled oligonucleotides were incubated Bahou, W.F. (2003). Protease-activated receptors. Curr. Top. Dev.
with 30 g nuclear protein extracts at room temperature for 20 min Biol. 54, 343–369.
in the reaction buffer (Roche). Nuclear extracts incubated with NF-
Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut,B consensus sequence were run immediately on 4% native poly-
J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterband,acrylamide gel in 0.25 TBE. The gel was transferred to Nitron
J.D., Ely, E.W., and Fisher, C.J., Jr. (2001). Efficacy and safety ofmembrane (Amersham) and the signal detected according to the
recombinant human activated protein C for severe sepsis. N. Engl.manufacturer’s manual (Roche).
J. Med. 344, 699–702.
Bonfoco, E., Krainc, D., Ankarcrona, M., Nicotera, P., and Lipton,
Intrastriatal NMDA Microinjections in Mice S.A. (1995). Apoptosis and necrosis: two distinct events induced,
All procedures were done in accordance with protocols approved respectively, by mild and intense insults with N-methyl-D-aspartate
by the University of Rochester. Male C57BL/6J mice, PAR1 null or nitric oxide/superoxide in cortical cell cultures. Proc. Natl. Acad.
(Coughlin, 2000), PAR3 null, and PAR4 null mice (Nakanishi-Matsui Sci. USA 92, 7162–7166.
et al., 2000) weighing 23–25 g were anesthetized with i.p. ketamine
Bru¨ne, B., and Schneiderhan, N. (2003). Nitric oxide evoked p53-(100 mg/kg) and xylazine (10 mg/kg). Animals received micro-infu-
accumulation and apoptosis. Toxicol. Lett. 139, 119–123.sions into the right striatum (0.5 mm anterior, 2.5 mm lateral, 3.2
Budd, S.L., Tenneti, L., Lishnak, T., and Lipton, S.A. (2000). Mito-mm ventral to the bregma) of either vehicle, NMDA (20 nmol in 0.3
chondrial and extramitochondrial apoptotic signaling pathways inl of PBS [pH 7.4]), NMDA  recombinant mouse APC (0.002 g or
cerebrocortical neurons. Proc. Natl. Acad. Sci. USA 97, 6161–6166.0.02 g or 0.2 g), NMDA  APC (0.2 g)  anti-PAR1 (H-111, 0.2
g) or anti-PAR2 (SAM 11, 0.2 g) or anti-PAR3 (H-103, 0.2 g) Cheng, T., Liu, D., Griffin, J.H., Fernandez, J.A., Castellino, F., Rosen,
antibodies. The solutions were infused over 2 min using a micro- E.D., Fukudome, K., and Zlokovic, B.V. (2003). Activated protein C
injection system (World Precision Instruments, Sarasota, FL). The blocks p53-mediated apoptosis in ischemic human brain endothe-
needle was left in place for an additional 8 min after the injection lium and is neuroprotective. Nat. Med. 9, 338–342.
as reported (Ayata et al., 1997). After 48 hr, mice were sacrificed Cregan, S.P., Fortin, A., MacLaurin, J.G., Callaghan, S.M., Cecconi,
under deep anesthesia for analysis of exitotoxic lesions. Mice were F., Yu, S.W., Dawson, T.M., Dawson, V.L., Park, D.S., Kroemer, G.,
transcardially perfused with PBS (pH 7.4) followed by 4% paraform- and Slack, R.S. (2002). Apoptosis-inducing factor is involved in the
aldehyde. The brains were removed and coronal sections at a 30 regulation of caspase-independent neuronal cell death. J. Cell Biol.
m thickness were prepared using Vibratome. Every fifth section 158, 507–517.
1 mm anterior and posterior to the site of injection was stained with
Coughlin, S.R. (2000). Thrombin signaling and protease-activatedcresyl violet. The lesion area was identified by the loss of staining
receptors. Nature 407, 258–264.as reported (Ayata et al., 1997). The lesion areas were determined
Coughlin, S.R., and Camerer, E. (2003). PARticipation in inflamma-by an image analyzer (Image-ProPlus, Media Cybernetics, Silver
tion. J. Clin. Invest. 111, 25–27.Spring, MD) and integrated to obtain the volume of injury.
Dawson, V.L., Dawson, T.M., London, E.D., Bredt, D.S., and Snyder,
S.H. (1991). Nitric oxide mediates glutamate neurotoxicity in primaryStatistical Analysis
cortical cultures. Proc. Natl. Acad. Sci. USA 88, 6368–6371.Data were presented as mean  SEM. ANOVA was used to deter-
Djebaili, M., Rondouin, G., Baille, V., and Bockaert, J. (2000). p53mine statistically significant differences. p  0.05 was considered
and Bax implication in NMDA induced-apoptosis in mouse hippo-statistically significant.
campus. Neuroreport 11, 2973–2976.
Domotor, E., Benzakour, O., Griffin, J.H., Yule, D., Fukudome, K.,
Acknowledgments
and Zlokovic, B.V. (2003). Activated Protein C alters cytosolic cal-
cium flux in human brain endothelium via binding to endothelial
This work was supported by US National Institutes of Health grant
protein C receptor and activation of protease activated receptor-1.
HL63290 and by Socratech LLC. PAR1 null, PAR3 null, and PAR4
Blood 101, 4797–4801.
null mice were generously provided by Dr. S. Coughlin. The authors
Donovan, F.M., and Cunningham, D.D. (1998). Signaling pathwaysgratefully acknowledge Dr. A. Gale and Ms. Xiao Xu for providing
involved in thrombin-induced cell protection. J. Biol. Chem. 273,Ser360Ala-APC and recombinant mouse protein C. We thank Dr.
12746–12752.Ning Tong for technical assistance with brain lesion experiments.
Drs. Zlokovic and Griffin serve as consultants for Socratech, LLC. Du, Y.S., Bales, K.R., Dodel, R.C., Hamilton-Byrd, E., Horn, J.W.,
Neuron
572
Czilli, D.L., Simmons, L.K., Ni, B., and Paul, S.M. (1997). Activation Ruf, W. (2003). PAR1 signaling: more good than harm? Nat. Med.
9, 258–260.of a caspase 3-related cysteine protease is required for glutamate-
mediated apoptosis of cultured cerebellar granule neurons. Proc. Ryan, K.M., Ernst, M.K., Rice, N.R., and Vousden, K.H. (2000). Role
Natl. Acad. Sci. USA 94, 11657–11662. of NF-kappaB in p53-mediated programmed cell death. Nature
404, 892–897.Fernandez, J.A., Xu, X., Liu, D., Zlokovic, B.V., and Griffin, J.H. (2003).
Recombinant murine activated protein C is neuroprotective in a Sakhi, S., Bruce, A., Sun, N., Tocco, G., Baudry, M., and Schreiber,
murine ischemic stroke model. Blood Cells Mol. Dis. 30, 271–276. S.S. (1997). Induction of tumor suppressor p53 and DNA fragmenta-
tion in organotypic hippocampal cultures following excitotoxin treat-Gabriel, B., Sureeau, F., Casselyn, M., Teissie, J., and Petit, P.X.
ment. Exp. Neurol. 145, 81–88.(2003). Retroactive pathway involving mitochondria in electroloaded
cytochrome c-induced apoptosis. Exp. Cell Res. 289, 195–210. Shibata, M., Kumar, S.R., Amar, A., Fernandez, J.A., Hofman, F.,
Griffin, J.H., and Zlokovic, B.V. (2001). Anti-Inflammatory, antithrom-Griffin, J.H., Zlokovic, B.V., and Fernandez, J.A. (2002). Activated
botic, and neuroprotective effects of activated protein C in a murineprotein C: potential therapy for severe sepsis, thrombosis, and
model of focal ischemic stroke. Circulation 103, 1799–1805.stroke. Semin. Hematol. 39, 197–205.
Striggow, F., Riek, M., Breder, J., Henrich-Noack, P., Reymann, K.G.,Isermann, B., Sood, R., Pawlinski, R., Zogg, M., Kalloway, S., Degen,
and Reiser, G. (2000). The protease thrombin is an endogenousJ.L., Mackman, N., and Weiler, H. (2003). The thrombomodulin-pro-
mediator of hippocampal neuroprotection against ischemia at lowtein C system is essential for the maintenance of pregnancy. Nat.
concentrations but causes degeneration at high concentrations.Med. 9, 331–337.
Proc. Natl. Acad. Sci. USA 97, 2264–2269.
Jordan, J., Galindo, M.F., Gonzalez-Garcia, C., and Cena, V. (2003).
Striggow, F., Riek-Burchardt, M., Kiesel, A., Schmidt, W., Henrich-Role and regulation of p53 in depolarization-induced neuronal
Noack, P., Breder, J., Krug, M., Reymann, K.G., and Reiser, G. (2001).death. Neuroscience 122, 707–715.
Four different types of protease-activated receptors are widely ex-
Joyce, D.E., Gelbert, L., Ciaccia, A., DeHoff, B., and Grinnell, B.W. pressed in the brain and are up-regulated in hippocampus by severe
(2001). Gene expression profile of antithrombotic protein C defines ischemia. Eur. J. Neurosci. 14, 595–608.
new mechanisms modulating inflammation and apoptosis. J. Biol.
Susin, S.A., Lorenzo, H.K., Zamzami, N., Marzo, I., Snow, B.E., Broth-Chem. 276, 11199–11203.
ers, G.M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., et
Kemp, J.A., and McKernan, R.M. (2002). NMDA receptor pathways al. (1999). Molecular characterization of mitochondrial apoptosis-
as drug targets. Nat. Neurosci. 5, 1039–1042. inducing factor. Nature 397, 441–446.
Kuliopulos, A., Covic, L., Seeley, S.K., Sheridan, P.J., Helin, J., and Tenneti, L., and Lipton, S.A. (2000). Involvement of activated cas-
Costello, C.E. (1999). Plasmin desensitization of the PAR1 thrombin pase-3 like protease in N-methyl-D-aspartate-induced apoptosis in
receptor: kinetics, sites of truncation, and implications for thrombo- cerebrocortical neurons. J. Neurochem. 74, 134–142.
lytic therapy. Biochemistry 38, 4572–4585. Tieu, K., Zuo, D.M., and Yu, P.H. (1999). Differential effects of stauro-
Le, D.A., and Lipton, S.A. (2001). Potential and current use of sporine and retinoic acid on the vulnerability of the SH-SY5Y neuro-
N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of blastoma cells: involvement of bcl-2 and p53 proteins. J. Neurosci.
aging. Drugs Aging 18, 717–724. Res. 58, 426–435.
Matys, T., and Strickland, S. (2003). Tissue plasminogen activator Uberti, D., Belloni, M., Grilli, M., Spano, P., and Memo, M. (1998).
and NMDA receptor cleavage. Nat. Med. 9, 371–373. Induction of tumour-suppressor phosphoprotein p53 in the apopto-
sis of cultured rat cerebellar neurons triggered by excitatory aminoMcInnis, J., Wang, C., Anastasio, N., Hultman, M., Ye, Y., Salvemini,
acids. Eur. J. Neurosci. 10, 246–254.D., and Johnson, K.M. (2002). The role of superoxide and nuclear
Villunger, A., Michalak, E.M., Coultas, L., Mullauer, F., Bock, C.,factor-kappaB signaling in N-methyl-D-aspartate-induced necrosis
Ausserlechner, M.J., Adams, J.M., and Strasser, A. (2003). p53- andand apoptosis. J. Pharmacol. Exp. Ther. 301, 478–487.
drug-induced apoptotic responses mediated by BH3-only proteinsMorrison, R.S., Kinoshita, Y., Johnson, M.D., Guo, W., and Garden,
puma and noxa. Science 302, 1036–1038.G.A. (2003). p53-dependent cell death signaling in neurons. Neuro-
Vu, T.K.H., Hung, D.T., Wheaton, V.I., and Coughlin, S.R. (1991).chem. Res. 28, 15–27.
Molecular cloning of a functional thrombin receptor reveals a novelMosnier, L.O., and Griffin, J.H. (2003). Inhibition of staurosporine-
proteolytic mechanism of receptor activation. Cell 64, 1057–1068.induced apoptosis of endothelial cells by activated protein C re-
Wang, X. (2001). The expanding role of mitochondria in apoptosis.quires protease activated receptor-1 and endothelial protein C re-
Genes Dev. 15, 2922–2933.ceptor. Biochem. J. 373, 65–70.
Yu, S.W., Wang, H., Poitras, M.F., Coombs, C., Bowers, W.J., Feder-Nakanishi-Matsui, M., Zheng, Y.W., Sulciner, D.J., Welss, E.J., Lude-
off, H.J., Poirier, G.G., Dawson, T.M., and Dawson, V.L. (2002). Medi-man, M.J., and Coughlln, S.R. (2000). PAR3 is a cofactor for PAR4
ation of poly(ADP-Ribose) polymerase-1-dependent cell death byactivation by thrombin. Nature 404, 609–613.
apoptosis-inducing factor. Science 297, 259–263.
Nicole, O., Docagne, F., Ali, C., Margaili, I., Carmeliet, P., MacKenzie,
E.T., Vilien, D., and Buisson, A. (2001). The proteolytic activity of
tissue-plasminogen activator enhances NMDA receptor-mediated
signaling. Nat. Med. 7, 59–64.
Okamoto, S., Li, Z., Ju, C., Scholzke, M.N., Mathews, E., Cui, J.,
Salvesen, G.S., Bossy-Wetzel, E., and Lipton, S.A. (2002). Dominant-
interfering forms of MEF2 generated by caspase cleavage contribute
to NMDA-induced neuronal apoptosis. Proc. Natl. Acad. Sci. USA
99, 3974–3979.
Paitel, E., Sunyach, C., Alves da Costa, C., Bourdon, J.C., Vincent,
B., and Checler, F. (2004). Primary cultured neurons devoid of cellu-
lar prion display lower responsiveness to staurosporine through the
control of p53 at both transcriptional and post-transcriptional levels.
J. Biol. Chem. 279, 612–618.
Penninger, J.M., and Kroemer, G. (2003). Mitochondria, AIF and
caspases-rivaling for cell death execution. Nat. Cell Biol. 5, 97–99.
Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M., and Ruf, W.
(2002). Activation of endothelial cell protease activated receptor 1
by the protein C pathway. Science 296, 1880–1882.
